To determine whether CCL9 and IL-23 release is the proximal trigger for the stromal changes that Myc activation elicits, adenoma-bearing KM mice were pre-treated with CCL9- and/or IL-23-blocking antibodies and Myc then activated by tamoxifen administration (Figures S1C and S1D). Here, MYC is linked to adenoma.